Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Rep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...
PMLive1d
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...
Barchart on MSN6d
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
BioPharma Dive5d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Truist Financial Keeps Their Buy Rating on Verona Pharma (VRNA)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Verona Pharma (VRNA – Research Report). The company’s ...
MoneyWeek on MSN5d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...
Corbus Pharmaceuticals (CRBP) Gets a Buy from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target ...
Yahoo Finance1d
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%. The past decade has ...